Latest News for: her2
Edit
Hastings Tribune
15 Jul 2026
Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-,
REVTORPYK is the first and only FDA-approved therapy ...
Edit
Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally ...
Nasdaq Globe Newswire 14 Jul 2026
Food and Drug Administration (“FDA”) approved REVTORPYK™ (gedatolisib) for the treatment of patients with hormone receptor positive (“HR+”), human ...
Edit
Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer (Celcuity Inc)
Public Technologies 14 Jul 2026
Edit
The Daily Record - Dunn
10 Jul 2026
Dr. Anna Voltura, Chair of HER2 Foundation, joins Santa Fe Cancer Center at Christus St. ...
This position with Christus St. Vincent is an opportunity to help more women battling breast cancer. Christus is known ....
Edit
DEP HER2 Investor Webinar (Starpharma Holdings Limited)
Public Technologies 07 Jul 2026
). The text version of this document is not available ... Disclaimer ... (noodl. 132932241) .
Edit
HER2 Positive Breast Cancer Pipeline Accelerates as 50+ Pharma Companies Rigorously Develop Drugs for Market ...
GetNews 04 Jul 2026
Edit
Positive DEP HER2-Lu preclinical data support Phase 1 entry (Starpharma Holdings Limited)
Public Technologies 02 Jul 2026
). The text version of this document is not available ... Disclaimer ... (noodl. 132844592) .
Edit
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors (Daiichi Sankyo Co Ltd)
Public Technologies 29 Jun 2026
). The text version of this document is not available ... Attachments Permalink. Disclaimer.
Edit
Enhertu� Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug ...
Business Wire 29 Jun 2026
Edit
Paolo Tarantino: Advancing MRD in HER2-Positive Breast Cancer (Personalis Inc)
Public Technologies 29 Jun 2026
). The text version of this document is not available ... Disclaimer. Personalis Inc.
Edit
Enhertu approved in the EU as first tumour agnostic HER2-directed therapy and antibody drug conjugate for patients with previously treated HER2-positive metastatic solid tumours (AstraZeneca plc)
Public Technologies 29 Jun 2026
The clinical utilisation and duration of treatment with HER2-directed therapies in HER2-positive recurrent or metastatic salivary gland cancers.
Edit
Enhertu approved in the EU as first tumour agnostic HER2-directed therapy and antibody drug conjugate for patients with previously treated HER2-positive metastatic solid tumours (Form 6-K) (AstraZeneca plc)
Public Technologies 29 Jun 2026
The clinical utilisation and duration of treatment with HER2-directed therapies in HER2-positive recurrent or metastatic salivary gland cancers.
Edit
Enhertu approved in EU for HER2+ solid tumours (AstraZeneca plc)
Public Technologies 29 Jun 2026
The clinical utilisation and duration of treatment with HER2-directed therapies in HER2-positive recurrent or metastatic salivary gland cancers.
Edit
Gentler Regimen for HER2+ Breast Cancer Gets Good Grades in 5-Year Report (Personalis Inc)
Public Technologies 26 Jun 2026
). The text version of this document is not available ... Disclaimer. Personalis Inc.
Edit
OS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine Osteosarcoma (OS Therapies Inc)
Public Technologies 26 Jun 2026
) OS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine Osteosarcoma ... 20% of OST-HER2 treated dogs survived 2-year vs ... Survival for OST-HER2+radiation vs.
- 1
- 2
- Next page »